Featured Story | By Nick Paul Taylor CureVac has shared phase 1/2 data on its COVID-19 vaccine candidate CVnCoV. The German biotech said the mRNA vaccine dose selected for further development sparked increases in virus-neutralizing antibodies and early indications of T-cell activation. read more |
| |
|---|
|
|  | For oncology CROs, the utilization of noninvasive optical imaging gives researchers an earlier indication of anti-cancer activity and valuable insight into the effects of new drugs. Our free white paper details its benefits and how this method can advance your drug program. Read more! |
Top Stories By Amirah Al Idrus Regeneron paused the phase 2 trial of its rare bone disease drug after multiple patients died in the extension part of the study. The company is reviewing the data “to better understand” the drug’s benefit-risk profile and has alerted regulators and the study’s independent data monitoring committee to the deaths. read more By Nick Paul Taylor Sanofi has struck a deal to buy Kiadis for €308 million ($358 million). The takeover will give Sanofi full control of an off-the-shelf natural killer cell platform it is already using to try to enhance its multiple myeloma drug Sarclisa. read more Sponsored By: WCG Are you looking to optimize your site’s patient recruitment advertising dollars? WCG’s experienced team of patient recruitment experts can help your site efficiently use your advertising funds by creating customized recruitment campaigns for any of your studies, and we’ve also curated a list of best practices to ensure your spend sees the best ROI. read more By Amirah Al Idrus When Joe Jimenez left Novartis, one thing was clear: After 11 years in the biopharma biz and eight at the Swiss drugmaker’s helm, he was ready to build something from scratch. Now, he’s unveiling that something: Aditum Bio, a biotech investment firm he co-founded with Mark Fishman, M.D., former president of the Novartis Institutes for BioMedical Research. read more By Ben Adams Nearly one month ago, Santhera admitted defeat for its Duchenne muscular dystrophy drug idebenone, culling the program. read more By Arlene Weintraub Startup Pandion Therapeutics is developing drugs that selectively activate the immune checkpoint PD-1 to treat autoimmune diseases. It recently presented promising preclinical data on drug candidates to treat graft-versus-host disease, kidney inflammation, vitiligo and other immune conditions. read more By Conor Hale LabCentral has launched a collaborative project to help test and validate quick, simple diagnostics for COVID-19 that people can use to screen themselves at home. read more Resources Sponsored By: AmerisourceBergen How pharma's supply chain partners are paving the way for coronavirus therapies. Sponsored By: Lonza Liquid-filled hard capsule formulations offer unique options for the manufacture and dosing of highly potent actives. Sponsored By: Thermo Fisher Scientific Anticipate early development challenges to avoid rework and costs. Sponsored By: Cytiva Accelerating the production of viral-vector based therapy requires both understanding of strategies to address viral vector manufacturing and how to select the most cost-effective solution for your therapeutic. Read more in this article. Sponsored by: LexisNexis Risk Solutions Get insights into healthcare decision-makers networks. Sponsored By: Veeva Learn how to plan immersive digital event experiences Sponsored by: Aldevron Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience. Sponsored By: Elligo Health Research® Understanding the Challenges COVID-19 Pediatric Clinical Trials Face | White Paper Sponsored By: Outer Edge Technology A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Cascade Chemistry, API CDMO Struggling with complex chemistry to get APIs for clinical trials? Find out what to look for in an API CDMO partner to gain expertise and speed that lead to success. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Formedix Learn how to save time and reduce costs and complexity by streamlining the clinical trial process. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
